Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-

PET clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation,

with respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related

to our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in Amendment No. 3 to our Registration

Statement on Form S-3, filed with the SEC October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... December 22, 2014 Fertility Associates of ... Egg Bank USA , a network of more than ... this partnership, patients have fast access to a national ... fertilization, IVF . Fertility Associates of Memphis is the ... fertility treatment option. , Dr. William Kutteh , ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... December 18, 2014 Today, ... its pilot production facility and future company headquarters ... produce innovative new materials that safely and effectively ... only because of its historic, strong support for ... to attract leading edge, technology-based companies such as ...
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... Shandong, China, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China,Biologic ... Biologic," or the,"Company"), one of the leading ... China ("PRC"), operating through its indirect,majority-owned subsidiaries, ... Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") ...
... NEUCHATEL, Switzerland, September 10 Elsevier,a ... services, today announced it has become one of the ... seat on the board at the first InChI Trust ... Originally developed by the International Union of Pure and ...
... , , , ... launch of QIAGEN,s new QIAsafe DNA Blood Products, the first dry ... technology. , , The QIAsafe DNA Blood Products ... chain. Biomatrica,s SampleMatrix technology significantly simplifies transport and storage of blood ...
Cached Biology Technology:China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 2China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 3Elsevier Joins InChI Trust as a Charter Member 2Elsevier Joins InChI Trust as a Charter Member 3Elsevier Joins InChI Trust as a Charter Member 4QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 2QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 3QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... infections may induce subtle neurological changes in the unborn ... neurodevelopmental disorders including schizophrenia and autism. Research published in ... into how this may happen and suggests potential strategies ... associated with increased risk of damage to the developing ...
... Oct. 12 Location Labs, the leader in providing ... an industry leader in identity validation and fraud detection, ... using Location Labs, Universal Location Service (ULS). Finsphere,s new ... to fight identity theft and validate consumer identity, and ...
... who don,t eat for several days are at greater ... study published in CMAJ ( Canadian Medical Association Journal ... The study, by Italian researchers, involved 1274 adults admitted ... were bedridden, admitted for same-day surgery or procedure, or ...
Cached Biology News:Location Labs Helps Power Finsphere's New Fraud Detection Product 2Location Labs Helps Power Finsphere's New Fraud Detection Product 3Malnutrition increases risk of prolonged hospital stay 2
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: